Selected article for: "mechanical ventilation therapy and ventilation therapy"
Author: Ibáñez, Sebastián; Martínez, Oriela; Valenzuela, Francisca; Silva, Francisco; Valenzuela, Omar
Title: Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
  • Cord-id: 87b298uk
  • Document date: 2020_6_3
    • ID: 87b298uk
    Snippet: The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical vent
    Document: The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and adequate monitoring: 1
    • action mechanism and low toxicity: 1, 2, 3, 4, 5, 6, 7
    • action mechanism and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action mechanism and lupus rheumatoid arthritis: 1, 2, 3, 4, 5
    • action mechanism study and acute ards respiratory distress syndrome: 1
    • activation phosphorylation and acute ards respiratory distress syndrome: 1
    • activation phosphorylation and lung infection: 1
    • acute ards respiratory distress syndrome and low number: 1
    • acute ards respiratory distress syndrome and low toxicity: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low volume: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
    • acute ards respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • acute ards respiratory distress syndrome development and low volume: 1
    • acute ards respiratory distress syndrome development and lung infection: 1, 2, 3, 4, 5, 6
    • adequate monitoring and low number: 1, 2
    • adequate monitoring and lung infection: 1